All In Biotech

Drug Trial Radar · NCT01289990

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23

Last checked: Nov 19, 2026Latest source record: Jul 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,705

Actual

Start

Feb 2011

Primary completion

May 2013

Study completion May 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Feb 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • BI 10773Drug

    BI 10773 tablets once daily

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • PlaceboDrug

    Placebo matching Sitagliptin

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • BI 10773Drug

    BI 10773 tablets once daily

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • BI 10773Drug

    BI 10773 tablets once daily

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • PlaceboDrug

    Placebo matching Sitagliptin

  • BI 10773Drug

    BI 10773 tablets once daily

  • BI 10773Drug

    BI 10773 tablets once daily

  • BI 10773Drug

    BI 10773 tablets once daily

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • BI 10773Drug

    BI 10773 tablets once daily

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • PlaceboDrug

    Placebo matching Sitagliptin

  • Sitagliptin 100mgDrug

    Sitagliptin once daily

  • BI 10773Drug

    BI 10773 tablets once daily

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • PlaceboDrug

    Placebo matching BI 10773 low dose

  • PlaceboDrug

    Placebo matching BI 10773 high dose

  • PlaceboDrug

    Placebo matching BI 10773 high dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of TreatmentTime frame: Baseline and 52 weeks
  2. Changes From Baseline in HbA1c (%) After 76 Weeks of TreatmentTime frame: Baseline and 76 weeks

Locations

243 sites in 19 countries. Site status is shown where the registry gives one.

  • 1245.31.10145 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1245.31.10162 Boehringer Ingelheim Investigational Site

    Glendale, Arizona

  • 1245.31.10124 Boehringer Ingelheim Investigational Site

    Mesa, Arizona

  • 1245.31.10108 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 1245.31.10046 Boehringer Ingelheim Investigational Site

    Tempe, Arizona

  • 1245.31.10154 Boehringer Ingelheim Investigational Site

    Chino, California

  • 1245.31.10149 Boehringer Ingelheim Investigational Site

    Rancho Cucamonga, California

  • 1245.31.10131 Boehringer Ingelheim Investigational Site

    West Hills, California

  • 1245.31.10038 Boehringer Ingelheim Investigational Site

    Northglenn, Colorado

  • 1245.31.10127 Boehringer Ingelheim Investigational Site

    Waterbury, Connecticut

  • 1245.31.10137 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1245.31.10133 Boehringer Ingelheim Investigational Site

    Jupiter, Florida

  • 1245.31.10006 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1245.31.10085 Boehringer Ingelheim Investigational Site

    Plantation, Florida

  • 1245.31.10080 Boehringer Ingelheim Investigational Site

    Decatur, Georgia

  • 1245.31.10077 Boehringer Ingelheim Investigational Site

    Perry, Georgia

  • 1245.31.10001 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 1245.31.10159 Boehringer Ingelheim Investigational Site

    Des Moines, Iowa

  • 1245.31.10014 Boehringer Ingelheim Investigational Site

    Dubuque, Iowa

  • 1245.31.10117 Boehringer Ingelheim Investigational Site

    Arkansas City, Kansas

  • 1245.31.10157 Boehringer Ingelheim Investigational Site

    Newton, Kansas

  • 1245.31.10146 Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • 1245.31.10003 Boehringer Ingelheim Investigational Site

    Dearborn, Michigan

  • 1245.31.10059 Boehringer Ingelheim Investigational Site

    New Hyde Park, New York

  • 1245.31.10034 Boehringer Ingelheim Investigational Site

    Rochester, New York

  • 1245.31.10123 Boehringer Ingelheim Investigational Site

    Smithtown, New York

  • 1245.31.10071 Boehringer Ingelheim Investigational Site

    Asheboro, North Carolina

  • 1245.31.10086 Boehringer Ingelheim Investigational Site

    Salisbury, North Carolina

  • 1245.31.10129 Boehringer Ingelheim Investigational Site

    Carlisle, Ohio

  • 1245.31.10045 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1245.31.10119 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1245.31.10130 Boehringer Ingelheim Investigational Site

    Gallipolis, Ohio

  • 1245.31.10158 Boehringer Ingelheim Investigational Site

    Mt. Pleasant, South Carolina

  • 1245.31.10015 Boehringer Ingelheim Investigational Site

    Simpsonville, South Carolina

  • 1245.31.10033 Boehringer Ingelheim Investigational Site

    Chattanooga, Tennessee

  • 1245.31.10112 Boehringer Ingelheim Investigational Site

    Memphis, Tennessee

  • 1245.31.10156 Boehringer Ingelheim Investigational Site

    Houston, Texas

  • 1245.31.10151 Boehringer Ingelheim Investigational Site

    Hurst, Texas

  • 1245.31.10143 Boehringer Ingelheim Investigational Site

    Killeen, Texas

  • 1245.31.10155 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

Showing 40 of 243 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.